Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner. It also provides immunohistochemistry products including automatic antigen repair instrument and automatic immunocytochemical staining machine, as well as conversional pathology equipment. The company was founded in 2005 and is based in Guangzhou, China.
Stock data | 2024 | Change |
---|---|---|
Price | $2.09 | N/A |
Market Cap | $195.67M | N/A |
Shares Outstanding | 93.57M | N/A |
Employees | 872.00 | N/A |